Amyris (NASDAQ:AMRS – Get Rating) had its target price dropped by equities researchers at HC Wainwright from $22.00 to $5.00 in a research report issued to clients and investors on Thursday, The Fly reports. HC Wainwright’s price objective would indicate a potential upside of 293.70% from the company’s previous close.
Separately, Piper Sandler dropped their price target on Amyris from $2.50 to $2.00 in a research report on Tuesday, January 3rd. One analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. According to data from MarketBeat.com, Amyris has an average rating of “Hold” and an average price target of $4.63.
Amyris Stock Down 3.8 %
Shares of AMRS opened at $1.27 on Thursday. The business’s 50 day moving average price is $1.45 and its 200-day moving average price is $2.10. Amyris has a 52 week low of $0.99 and a 52 week high of $5.15. The stock has a market cap of $419.30 million, a P/E ratio of -0.72 and a beta of 1.10.
Hedge Funds Weigh In On Amyris
Amyris, Inc engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.
- Get a free copy of the StockNews.com research report on Amyris (AMRS)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.